

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Accelmed Partners, L.P.</u> (Last) (First) (Middle) C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE, SUITE 140 (Street) HORSHAM PA 19044 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>STRATA Skin Sciences, Inc. [SSKN]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/15/2024</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/15/2024		P		230,573	A	\$3.14	1,441,835	D	
Common Stock								1,441,835	I	By: Accelmed Growth Partners (GP), L.P. ⁽¹⁾
Common Stock								1,441,835	I	By: Accelmed Growth Partners (AGP), Ltd. ⁽¹⁾
Common Stock								1,441,835	I	By: Accelmed Management Ltd. ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>Accelmed Partners, L.P.</u> (Last) (First) (Middle) C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE, SUITE 140 (Street) HORSHAM PA 19044 (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Accelmed Partners (GP), L.P.</u>

(Last) (First) (Middle)

C/O STRATA SKIN SCIENCES, INC.
5 WALNUT GROVE DRIVE, SUITE 140

(Street)
HORSHAM PA 19044

(City) (State) (Zip)

1. Name and Address of Reporting Person *

[Accelmed Growth Partners \(AGP\) Ltd](#)

(Last) (First) (Middle)

C/O STRATA SKIN SCIENCES, INC.
5 WALNUT GROVE DRIVE, SUITE 140

(Street)
HORSHAM PA 19044

(City) (State) (Zip)

1. Name and Address of Reporting Person *

[Accelmed Growth Partners Management Ltd.](#)

(Last) (First) (Middle)

C/O STRATA SKIN SCIENCES, INC.
5 WALNUT GROVE DRIVE, SUITE 140

(Street)
HORSHAM PA 19044

(City) (State) (Zip)

Explanation of Responses:

1. Shares are held directly by Accelmed Partners, L.P. and may be deemed to be beneficially owned indirectly by (i) Accelmed Partners (GP), L.P., the general partner of Accelmed Partners, L.P., (ii) Accelmed Growth Partners (AGP) Limited, the general partner of Accelmed Partners (GP), L.P., and (iii) Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the shares pursuant to a management agreement. Each of Accelmed Partners (GP), L.P., Accelmed Growth Partners (AGP) Limited, and Accelmed Growth Partners Management Ltd. disclaims such beneficial ownership except to the extent of their pecuniary interest in the shares of common stock held by Accelmed Partners, L.P.

[Accelmed Partners, L.P. By:](#)
[Accelmed Partners \(GP\), L.P.,](#)
[its general partner By:](#)
[Accelmed Growth Partners](#) 07/17/2024
[\(AGP\) Ltd., its general partner](#)
[By: /s/ Uri Geiger, Managing](#)
[Partner](#)
[Accelmed Partners \(GP\), L.P.](#)
[By: Accelmed Growth](#)
[Partners \(AGP\) Ltd., its](#) 07/17/2024
[general partner By: /s/ Uri](#)
[Geiger, Managing Partner](#)
[Accelmed Growth Partners](#)
[\(AGP\) Ltd. By: /s/ Uri Geiger,](#) 07/17/2024
[Managing Partner](#)
[Accelmed Growth Partners](#)
[Management Ltd. By: /s/ Uri](#) 07/17/2024
[Geiger, Managing Partner](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.